1. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial
- Author
-
Shiho Yamamoto, Hisanori Ito, Takushi Kanazu, Shunsuke Einaru, Shuji Yonezawa, Norihiko Tanimoto, Takahiko Yamamoto, Luc Tritsmans, Takuya Oguma, Akira Kato, Gaku Sakaguchi, Ken-ichi Kusakabe, Katsunori Sakai, Tatsuhiko Ueno, Akihiro Matsuda, Akihiro Hori, Kenji Morimoto, Yoshitaka Yamaguchi, Yoshiyasu Baba, Maarten Timmers, Naoya Asada, and Koriyama Yuji
- Subjects
Male ,ERG1 Potassium Channel ,Pyridines ,medicine.medical_treatment ,Irreversible binding ,Thiazines ,Covalent binding ,Pharmacology ,01 natural sciences ,Rats, Sprague-Dawley ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,Dogs ,Alzheimer Disease ,β amyloid ,Thiazine ,Drug Discovery ,medicine ,Amyloid precursor protein ,Animals ,Aspartic Acid Endopeptidases ,Humans ,Protease Inhibitors ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Amyloid beta-Peptides ,Protease ,biology ,Chemistry ,0104 chemical sciences ,Clinical trial ,010404 medicinal & biomolecular chemistry ,Enzyme ,Early Termination of Clinical Trials ,biology.protein ,Molecular Medicine ,Female ,Amyloid Precursor Protein Secretases - Abstract
Accumulation of amyloid β peptides (Aβ) is thought to be one of the causal factors of Alzheimer's disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the rate-limiting protease for Aβ production, and therefore, BACE1 inhibition is a promising therapeutic approach for the treatment of AD. Starting with a dihydro-1,3-thiazine-based lead, Compound J, we discovered atabecestat 1 (JNJ-54861911) as a centrally efficacious BACE1 inhibitor that was advanced into the EARLY Phase 2b/3 clinical trial for the treatment of preclinical AD patients. Compound 1 demonstrated robust and dose-dependent Aβ reduction and showed sufficient safety margins in preclinical models. The potential of reactive metabolite formation was evaluated in a covalent binding study to assess its irreversible binding to human hepatocytes. Unfortunately, the EARLY trial was discontinued due to significant elevation of liver enzymes, and subsequent analysis of the clinical outcomes showed dose-related cognitive worsening.
- Published
- 2021
- Full Text
- View/download PDF